Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose, dose-escalation study of LY2127399 in rheumatoid arthritis
jRCT2080221342Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tabalumab in rheumatoid arthritis (RA) (6 arms), sponsored by Eli Lilly and Company.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221342.